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Abstract
Background: In order to minimize the amount of incomplete follow-up data, reducing the non-
compliance of participating physicians is one of the key issues for the data coordinating center in a
multi-center trial. Identifying the physicians' non-compliance in advance is considered to be an
important strategy for more efficient conduct of trials. In this study, we identified physicians'
characteristics and factors associated with the need for individual visits to institutions to collect
data or to complete information during two years of follow-up in a large Japanese investigator-
initiated trial related to cardiovascular disease.
Methods: We categorized the physicians into two groups, "complier" and "non-complier". Odds
ratios and corresponding 95% confidence intervals were calculated for 11 factors related to the
characteristics of and compliance by physicians. Multiple logistic regression analysis was also
performed. In addition, we evaluated the incremental cost for obtaining additional information of
the non-compliant physicians.
Results: Three factors were identified in multiple logistic regression analysis as being significantly
associated with compliance status: 1) prior participation in clinical trials (OR = 0.40 95%CI = 0.21–
0.74); 2) physician opinion that the support system for case registration and follow-up was well
organized (OR = 0.41 95%CI = 0.22–0.75); and 3) number of patients recruited (OR = 2.25 95%CI
= 1.01–5.02). The actual incremental cost was about US $112,000 (14.4% of total routine follow-
up costs) for the non-compliant physicians during the 2 years, or about US $570 per patient.
Conclusion: Investigator-initiated clinical trials have recently attracted great interest, but they
often suffer from insufficient funding. If trial networks are to be well organized, it is important that
trials are conducted more efficiently. We believe that our findings will be useful for reducing the
additional burden associated with incomplete follow-up data and data lost to follow-up when
planning future trials.
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Background
Limiting the number of patients lost to follow-up is essen-
tial for the successful completion of randomized control-
led trials (RCT). In a multi-center trial, the data
coordinating center is mainly responsible for locating
patients who are lost during the treatment and follow-up,
and persuading them to rejoin the trial [1]. However, it is
usually difficult for the coordinating center staff to contact
the patients directly, especially if the number of centers is
large. Therefore, the coordinating center takes a variety of
approaches to the participating physicians to monitor the
state of achievement of trials periodically and encourage
or help the participating institutions to collect accurate
information in order to prevent loss to follow-up. For
example, reminder letters or newsletters may often be sent
to the participating physicians. However, if the physicians
seem to be reluctant to submit the necessary periodic
reports or don't give the information about their patients,
clinical research coordinators (CRC) or principal investi-
gators belonging to the coordinating center may ulti-
mately have to visit the institutions. These additional
approaches involve considerable time, labor, and cost, if
there are many such physicians or the trials were contin-
ued over the long-term. For practical clinical trials, it is
essential to perform such additional work as efficiently as
possible.
In a multi-center trial, the coordinating center mainly con-
tacts the individual physicians or clinical staff. If the coor-
dinating center could identify in advance what kind of
physicians don't report their case report forms (CRF) peri-
odically to the coordinating center, it might lead to an
important strategy for more efficient conduct of such tri-
als. However, there has not been much attention focused
on what factors are associated with physicians' compli-
ance to date. The objective of the study presented here was
to identify the physician factors associated with the need
for special visits from coordinating center staff or with




We used data from a large-scale randomized clinical trial
known as the Candesartan Antihypertensive Survival Eval-
uation in Japan (CASE-J). CASE-J is a prospective, multi-
center, open-label, investigator-initiated RCT for high-risk
hypertensive patients. The objective is to compare the
effectiveness of an angiotensin II receptor antagonist (can-
desartan cilexetil) and of a calcium channel blocker
(amlodipine besilate) in terms of the incidence of cardio-
vascular events [2]. Enrollment began in September 2001
and 4,728 patients had been recruited by December 2002.
This is one of only a few large investigator-initiated RCT
in Japan and follow-up was to be completed in December
2005. We used 2 years (from January 2003 through
December 2004) of patient follow-up data from the
CASE-J trial.
For the CASE-J trial, contracts were made between partici-
pant physicians and the Evidence Based Medicine Collab-
orative Research Center (EBM Center) of the Kyoto
University Graduate School of Medicine. The follow-up
data were collected every 6 months. Nine central CRCs in
the EBM center were mainly responsible for coordinating
the data collection from participant physicians and for
receiving, editing, processing, and storing data generated
in the trial using a Web-based remote data entry system or
a fax-based system. A list with the dates of patients' exam-
inations and e-mail or fax reminders were periodically
sent to the participating physicians from 2 months before
the examination until the completed CRF had been
received. If the CRF had not been received 2 months or
more after the planned reporting date, CRCs reminded the
physicians to submit the periodic report. If, in spite of the
reminder, the report had still not been submitted, a CRC
and an investigator from the EBM center visited the insti-
tution in person to encourage and help with filling out the
CRF. This constitutes additional work. If no information
was received for a year or more, the eventual outcome is
likely to be that the patient data are lost to follow-up.
Categorization of participating physicians
Each periodic report of patients' data was categorized into
one of four mutually exclusive groups. The first was the
"complete dataset group", comprising periodic reports
submitted to the EBM center within the allowable time
window. The second was the "delayed group", comprising
reports not submitted within the allowable time window,
but eventually submitted without the need for a special
visit. The third was the "additional assistance group",
comprising periodic reports not sent in within the allow-
able time window, but finally submitted after additional
assistance by means of an actual visit to the institution.
The fourth was the "incomplete dataset group", where no
periodic reports at all were received by the EBM center.
Data unobtainable because of patient death were not con-
sidered to be part of the "incomplete dataset".
After the categorization of patients' datasets, we catego-
rized the physicians into two groups, "compliers" and
"non-compliers". Non-compliers were defined as physi-
cians with 50% or more of the data submitted categorized
as "additional assistance group" or "incomplete dataset
group". All other physicians were categorized as compli-
ers.
The questionnaire
Our questionnaire was previously described in the parent
study [3-5]. Briefly, the questionnaires were sent to allTrials 2006, 7:26 http://www.trialsjournal.com/content/7/1/26
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physicians participating in the CASE-J trial in January
2003, immediately after the patient recruitment period
ended in December 2002. For our study, we used the fol-
lowing physician characteristics (obtained at the start of
the follow-up): background factors (age, sex, prior partic-
ipation in a clinical trial, current participation in another
study, place of work, and use of Internet or fax for recruit-
ment and follow-up) and four reasons for participating in
CASE-J. These four reasons for participating in CASE-J
were: 1) the study protocol was simple; 2) a special inter-
est in the use of the Internet for case registration and fol-
low-up study; 3) expectation that it would be easy to
persuade patients to participate in this study; and 4)
impression that the support system for case registration
and follow-up study was well organized.
Incremental cost for additional work
In addition, since it was unclear how much additional
work costs, we examined such costs in the context of
CASE-J. We defined the incremental cost for additional
tasks as the additional payment for the CRC plus addi-
tional cost for travel plus other overheads. Regular pay-
ment for the CRC and other recurring costs, including the
cost of regular meetings and normal overheads, were
defined as routine costs for the clinical trial.
During the follow-up stage, a fee per patient is routinely
paid to the physician concerned every time a periodic
report is submitted. If a cardiovascular event occurs, an
evaluation fee per patient is paid to the Event Evaluation
Committee. We excluded these fees from the total follow-
up cost in our study, as well as expenditures for mainte-
nance of the Web-based system and telephone or fax
charges, which were considered regular expenditures. All
additional costs were converted at a rate of 110 Japanese
yen to one US dollar.
Statistical analysis
P values were calculated based on the χ2 test. Odds ratios
and corresponding 95% confidence intervals (95% CI)
were computed for the various background factors of the
physicians and the number of patients they recruited for a
comparison of compliers and non-compliers. If the odds
ratio was greater than 1.0, it was considered to indicate
that the factor might be associated with the non-complier
group. If the 95% CI did not include 1.0, we considered
the association to be significant. Multiple logistic regres-
sion analysis was also performed to adjust for the con-
founding factors and to evaluate predictive factors of the
non-complier group. We defined a non-complier as a phy-
sician with 50% or more of the data submitted catego-
rized as "additional assistance group" or "incomplete
dataset group". This threshold of 50% was arbitrary to
some degree. We therefore changed this threshold from
50% to from 10% to 90% for the sensitivity analysis. The
maximum change in odds ratios and P values were indi-
cated. Physicians' background factors and the number of
patients they recruited were assumed to be independent
variables. SAS for Windows, release 8.02 (SAS Institute
Inc., Cary, NC) was used for all analyses.
Results
Patients' dataset categorization
Failure to obtain written consent resulted in the exclusion
of 23 of the 4,728 patients entered in CASE-J. Datasets for
only eight of the remaining 4,705 patients were not sub-
mitted at all during the 2-year follow-up at December
2004.
Datasets for 700 (14.9%) of 4,705 patients were catego-
rized as "additional assistance group" or "incomplete
dataset group" during the 2-year follow-up. Data collec-
tion for 197 of these 700 patients were additionally
assisted by CRCs or investigators from the EBM center at
least once during the 2-year follow-up, while 168 (3.6%)
of the 4,705 patients withdrew their consent and 335
(7.1%) patient reports were not submitted at some time
during the 2-year follow-up.
Physicians' characteristics associated with the additional 
tasks
The questionnaire was returned by 448 of the 512
(87.5%) physicians, 22 of whom were excluded from this
analysis because 13 were anonymous and nine were
replaced during the follow-up period. Response propor-
tions for the questionnaire were 86.4% (357 of 413) for
the "complier" group and 69.7% (69 of 99) for the "non-
complier" group, showing a statistically significant differ-
ence (P < 0.001).
Table 1 shows a comparison between the "complier" and
"non-complier" groups in terms of physicians' character-
istics and the number of patients recruited. The latter was
skewed positively for both groups. Four factors were sig-
nificantly associated with (non-)compliance: Age over 50
(OR = 1.75; 95%CI = 1.01–3.05), prior participation in
clinical trials (OR = 0.43; 95%CI = 0.25–0.75), physicians
who thought the support system for case registration and
follow-up was well organized (OR = 0.46; 95%CI = 0.27–
0.78), and the number of patients recruited (OR = 2.31;
95%CI = 1.10–4.85).
Multiple logistic regression analysis showed similar
results for the various characteristics and factors. Prior par-
ticipation in clinical trials (OR = 0.40; 95%CI = 0.21–
0.74), physicians who thought the support system for case
registration and follow-up was well organized (OR = 0.41;
95%CI = 0.22–0.75), and the number of patients
recruited (OR = 2.25; 95%CI = 1.01–5.02) were also sig-
nificantly associated with (non-)compliance. The sensitiv-Trials 2006, 7:26 http://www.trialsjournal.com/content/7/1/26
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ity analysis was also done. The results generally tended to
be relatively similar even if the threshold was changed.
The odds ratios and p-values were changed as follows:
prior participation in clinical trials (OR = 0.39–0.55, P =
0.004–0.04), physicians who thought the support system
for case registration and follow-up was well organized
(OR = 0.41–0.59, P = 0.003–0.03), and the number of
patients recruited (OR = 1.75–2.74, P = 0.03–0.12).
The incremental cost for additional work
In addition, we examined the incremental cost for addi-
tional work, which was about US $112,000 (14.4% of the
total follow-up routine costs) and remained constant for
the 2 years of the follow-up. The average cost for addi-
tional tasks per patient amounted to about US $570.
Discussion
In this study, we investigated identified the physicians'
characteristics and factors associated with physician's
compliance and the incremental costs involved in addi-
Table 1: Physicians' factors and respective odds ratios
Non-Complier (n = 69) Complier (n = 357) Odds Ratio (95% CI)
Age
- mean (SD) 47.1 (7.2) 49.9 (8.4)
- median (range) 46 (31–67) 49 (31–77)
- <50 (%) 44 (66.7) 188 (53.3) 1.75a (1.01–3.05)
- 50 (%) 22 (33.3) 165 (46.7) -
Sex
- Male (%) 62 (92.5) 335 (94.6) 0.70 (0.25–1.95)
- Female (%) 5 (7.5) 19 (5.4)
Prior experience of participating in clinical trial
- Yes (%) 42 (62.7) 281 (79.6) 0.43a (0.25–0.75)
- No (%) 25 (37.3) 72 (20.4) -
Current participation in other study
- Yes (%) 44 (65.7) 245 (69.0) 0.86 (0.49–1.49)
- No (%) 23 (34.3) 110 (31.0) -
Working site
- University, national or private hospital (%) 30 (44.8) 133 (37.8) 1.34 (0.79–2.26)
- Own private clinic (%) 37 (55.2) 219 (62.2) -
Using Internet or FAX for recruitment and follow-up
- Using both (%) 14 (20.3) 72 (20.2) 0.78 (0.38–1.59)
- Using Internet (%) 28 (40.6) 176 (49.3) 0.64 (0.36–1.14)
- Using FAX (%) 27 (39.1) 109 (30.5) -
Simplicity of study protocol
- Agree (%) 36 (53.7) 205 (61.0) 0.74 (0.44–1.26)
- Neutral or Disagree (%) 31 (46.3) 131 (39.0) -
Special interest in the use of Internet for this trial
- Agree (%) 22 (32.8) 128 (38.7) 0.78 (0.44–1.35)
- Neutral or Disagree (%) 45 (67.2) 203 (61.3) -
Expectation that it would be easy to explain to patients about CASE-J
- Agree (%) 14 (20.6) 74 (21.9) 0.92 (0.49–1.76)
- Neutral or Disagree (%) 54 (79.4) 264 (78.1) -
Well-organized support system for case registration and follow-up
- Agree (%) 29 (43.3) 212 (62.5) 0.46a (0.27–0.78)
- Neutral or Disagree (%) 38 (56.7) 127 (37.5) -
Number of recruiting patients
- mean 5.9 (10.4) 10.3 (22.8)
- median (range) 2 (1–65) 4 (1–200)
- <10 (%) 60 (87.0) 265 (74.2) 2.31a (1.10–4.85)
- 10 (%) 9 (13.0) 92 (25.8) -
a: Significantly associatedTrials 2006, 7:26 http://www.trialsjournal.com/content/7/1/26
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tional work in a clinical trial. CASE-J is one of the few
studies that as a large-scale RCT in the cardiovascular dis-
ease field worked well in Japan. Investigator-initiated clin-
ical trials have recently been attracting great interest and
the results are considered more reliable than those of trials
conducted by pharmaceutical companies [6]. However,
investigator-initiated clinical trials often suffer from insuf-
ficient funding. If trial networks are to be well organized,
it is important that trials are conducted more efficiently.
Our results should therefore be useful for understanding
the situation in Japan and in conducting similar investiga-
tor-initiated clinical trials in the future.
The results of our multiple logistic regression analysis
showed that three factors were significantly associated
with non-compliance: prior participation in clinical trials,
physicians' opinion that this trial had a well-organized
support system for case registration and follow-up, and a
large number of patients recruited for the trial. The first
and second factors were to be expected, because prior
experience can provide the expertise needed for a new
clinical trial, and physicians who feel they are adequately
supported can submit their periodic report without seeing
it as an extra burden. On the other hand, we had expected
that a small number of patients would constitute a smaller
burden. However, the physicians who enrolled a large
number of patients tended to be more compliant. This
may indicate that physicians who enroll large number
patients are relatively more assertive about participation
in the trial and even if they miss a periodic report, they
tend to be more careful thereafter. In the sensitivity anal-
ysis, the third factor was partly not significant when the
threshold was 80 and 90%. However, this may be because
these threshold levels were too high and so the number of
Table 2: Multiple logistic regression analysis to identify predictors of "Non-Complier group"
Odds Ratio (95%CI)
Age
- <50 1.38 (0.75–2.55)
- 50 -
Sex
- Male 0.76 (0.25–2.32)
- Female -
Prior experience of participating in clinical trial
- Yes 0.40a (0.21–0.74)
- No -
Current participation in other study
- Yes 1.02 (0.56–1.87)
- No -
Working site
- University, national or private hospital 1.55 (0.86–2.80)
- Own private clinic -
Using Internet or FAX for recruitment and follow-up
- Using both 0.59 (0.30–1.15)
- Using Internet 0.59 (0.26–1.33)
- Using FAX -
Simplicity of study protocol
- Agree 0.84 (0.44–1.58)
- Neutral or Disagree -
Special interest in the use of Internet for this trial
- Agree 1.01 (0.53–1.94)
- Neutral or Disagree -
Expectation that it would be easy to explain to patients about CASE-J
- Agree 1.44 (0.67–3.11)
- Neutral or Disagree -
Well-organized support system for case registration and follow-up
- Agree 0.41a (0.22–0.75)
- Neutral or Disagree -
Number of recruiting patients
- <10 2.25a (1.01–5.02)
- 10 -
a: Significantly associatedTrials 2006, 7:26 http://www.trialsjournal.com/content/7/1/26
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physicians in the category of 10 recruited patients and
"complier" was reduced. The tendencies of odds ratio
were all similar and so the threshold of 50% might be
considered acceptable for this study.
There are some limitations to this study. First, because this
study targeted only Japanese subjects, ethnic or cultural
differences could not be taken into consideration so it is
not clear whether our findings can be generalized interna-
tionally. Second, other factors may influence the physi-
cian's compliance. If patients don't come to the hospital
periodically, don't comply with the protocol treatment, or
have difficulty with the patient-physician relationship, the
physicians may feel reluctant to submit the necessary peri-
odic reports. Identification of patient factors that influ-
ence patient's compliance and development of patient's
compliance strategies focused on patients have received
considerable attention [7-11]. Recently, the significance
of the interface between patients and clinical staff as a
potential factor in maintaining patient compliance has
also been reported [12]. We couldn't adjust for these fac-
tors because we didn't include them in our research, but
we may need to do so in future. Third, the results of this
study were based solely on the factors associated with
physicians' non-compliance, so it also remains unclear
whether intervention from the central data coordinating
center can lead to a reduction in non-compliance. Newell
et al.'s [13] review of physician-focused interventions,
such as the distribution of reminders and educational
materials, found that they had little effect. How to best
influence participant physicians should be the basis of
further study.
For CASE-J, the incremental cost for special assistance was
about 14.4% of the total follow-up cost during the 2-year
follow-up of 197 patients (4.2%) out of 4,705. This did
not include the cost of maintenance of the Internet-based
system and telephone or fax charges, the per-patient fee
for the physician's CRF, or the cost per patient charged by
the Event Evaluation Committee. It is difficult to assess
objectively whether this cost should be considered high or
not, because it can depend the situation of each of the par-
ticipating institutions. However, considering that the per-
centage of follow-up information that was not submitted
at some time during the 2-year follow-up was 7.1%, which
is relatively low, the cost might be considered reasonable.
Physicians' non-compliance often leads to loss to follow-
up. Investigators therefore always have to be careful to
minimize the quantity of incomplete information during
follow-up and make every effort to minimize data lost to
follow-up during randomized clinical trials. We believe
that our findings will be useful for reducing the additional
burden associated with incomplete follow-up data and
data lost to follow-up when planning future trials. In
future, we need to examine how to intervene to reduce
possible non-compliance factors.
Conclusion
We identified the physicians' factors associated with the
need for special visits from coordinating center staff or
with failure to supply complete information in an investi-
gator-initiated clinical trial. Our results are useful for
understanding of the situation in Japan and for conduct-
ing similar investigator-initiated clinical trials in the
future. In future, we need to examine how to intervene to
reduce possible non-compliance factors.
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